- Home
- NSTS vs SLS Comparison
NSTS vs SLS Comparison
Compare NSTS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- SLS
- Stock Information
- Founded
- NSTS 1921
- SLS 2012
- Country
- NSTS United States
- SLS United States
- Employees
- NSTS N/A
- SLS N/A
- Industry
- NSTS Savings Institutions
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- SLS Health Care
- Exchange
- NSTS Nasdaq
- SLS Nasdaq
- Market Cap
- NSTS 64.4M
- SLS 69.6M
- IPO Year
- NSTS N/A
- SLS N/A
- Fundamental
- Price
- NSTS $12.62
- SLS $1.49
- Analyst Decision
- NSTS
- SLS
- Analyst Count
- NSTS 0
- SLS 0
- Target Price
- NSTS N/A
- SLS N/A
- AVG Volume (30 Days)
- NSTS 4.5K
- SLS 5.3M
- Earning Date
- NSTS 03-27-2025
- SLS 03-27-2025
- Dividend Yield
- NSTS N/A
- SLS N/A
- EPS Growth
- NSTS N/A
- SLS N/A
- EPS
- NSTS N/A
- SLS N/A
- Revenue
- NSTS $6,117,000.00
- SLS N/A
- Revenue This Year
- NSTS N/A
- SLS N/A
- Revenue Next Year
- NSTS N/A
- SLS N/A
- P/E Ratio
- NSTS N/A
- SLS N/A
- Revenue Growth
- NSTS N/A
- SLS N/A
- 52 Week Low
- NSTS $9.35
- SLS $0.59
- 52 Week High
- NSTS $12.94
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- NSTS 70.09
- SLS 63.02
- Support Level
- NSTS $11.80
- SLS $1.24
- Resistance Level
- NSTS $12.94
- SLS $1.84
- Average True Range (ATR)
- NSTS 0.23
- SLS 0.22
- MACD
- NSTS 0.05
- SLS 0.05
- Stochastic Oscillator
- NSTS 79.45
- SLS 64.65
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.